Pfizer Cash Flow Statement
NYSE: PFEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:01 PM ET · Delayed 15 min
Pfizer free cash flow
In fiscal 2025, Pfizer generated $11.70 billion of operating cash flow and spent $2.63 billion on capital expenditures. That left free cash flow of $9.07 billion, a free-cash-flow margin of 14.5% of revenue. Free cash flow was down 7.7% from the prior year's $9.84 billion.
Pfizer returned $9.77 billion to shareholders through dividends, equal to 108% of free cash flow. Free cash flow covered dividend payments 0.9 times.
Summary generated from market data by MetaCap's automated system. Methodology
Pfizer cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 7.81B | 8.06B | 2.16B | 31.41B | 22.02B | 9.20B | 16.06B | 11.19B | 21.36B | 7.25B |
| Net Income growth (YoY) | -3.10% | +273.59% | -93.13% | +42.60% | +139.53% | -42.73% | +43.51% | -47.61% | +194.71% | +3.72% |
| Depreciation & Amortization | 6.59B | 7.01B | 6.29B | 5.06B | 5.19B | 4.68B | 5.75B | 6.38B | 6.27B | 5.76B |
| Stock-Based Compensation | 799.00M | 877.00M | 525.00M | 872.00M | 1.18B | 755.00M | 687.00M | 923.00M | 840.00M | 691.00M |
| Change in Working Capital | -2.55B | -1.72B | -1.19B | -5.09B | 13.97B | 933.00M | -828.00M | -171.00M | -112.00M | 832.00M |
| Operating Cash Flow | 11.70B | 12.74B | 8.70B | 29.27B | 32.58B | 14.40B | 12.59B | 15.83B | 16.80B | 16.19B |
| Capital Expenditures | -2.63B | -2.91B | -3.91B | -3.24B | -2.71B | -2.23B | -2.05B | -1.98B | -1.96B | -1.82B |
| Investing Cash Flow | -1.35B | 2.65B | -32.28B | -15.78B | -22.55B | -4.27B | -3.94B | 4.53B | -4.74B | -7.79B |
| Dividends Paid | -9.77B | -9.51B | -9.25B | -8.98B | -8.73B | -8.44B | -8.04B | -7.98B | -7.66B | -7.32B |
| Share Repurchases | — | 0 | 0 | -2.00B | 0 | 0 | -8.87B | -12.20B | -5.00B | -5.00B |
| Debt Issued | 9.68B | 0 | 30.83B | 0 | 997.00M | 5.22B | 4.94B | 4.97B | 5.27B | 10.98B |
| Debt Repaid | -6.76B | -2.25B | -2.57B | -3.30B | -2.00B | -4.00B | -6.81B | -3.57B | -6.15B | -7.69B |
| Financing Cash Flow | -10.30B | -17.14B | 26.07B | -14.83B | -9.82B | -9.65B | -8.48B | -20.44B | -13.35B | -9.23B |
| Net Change in Cash | 91.00M | -1.81B | 2.45B | -1.51B | 159.00M | 475.00M | 125.00M | -205.00M | -1.24B | -1.04B |
| Free Cash Flow | 9.07B | 9.84B | 4.79B | 26.03B | 29.87B | 12.18B | 10.54B | 13.84B | 14.85B | 14.37B |
This table shows 10 annual periods of Pfizer's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PFE's reporting calendar. What is a cash flow statement?